shutterstock_1843221310_maxshot_pl

MAXSHOT.PL / Shutterstock.com

13 February 2024Big PharmaLiz Hockley

GSK gets appeal go-ahead in licensing clash with AZ

Appeals court sides with GSK unit in licensing dispute over ovarian cancer drug | Judges find fault with previous decision ordering the pharma firm to pay royalties on all sales of an ovarian cancer treatment.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More on this story

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More on this story

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More features

Novo Nordisk targets Canada’s largest generics maker over diabetes drug

Jones Day hires pharma and high-tech patent litigator to London office

Powell Gilbert co-founder moves to US firm

GSK: ‘Whoever moves first has UPC advantage’

Pfizer and BioNTech win UK COVID-19 dispute

Roche to outside counsel: ‘Law firms must adapt to the modern world’

Astellas defends blockbuster cancer treatment patent

Regeneron denied safe harbour defence in COVID-19 drug dispute